DR. LIXIN ZHANG, M.D.
Medical Practice at Business Center Dr, Houston, TX
License number
Texas 265295
Category
Medical Practice
Type
Hematology
License number
Texas P4534
Category
Medical Practice
Type
Hematology
Address
Address
1140 Business Center Dr STE 370, Houston, TX 77043
Phone
(713) 271-4133
(713) 271-6885 (Fax)
(713) 271-6885 (Fax)
Personal information
See more information about LIXIN ZHANG at radaris.comName
Address
Phone
10008 Dark Star Ter, Austin, TX 78726
9519 Pemberton Trce, Houston, TX 77025
9506 Sandstone St, Houston, TX 77036
7015 Dusty Rose Cir, Sugar Land, TX 77479
2802 Lariat Canyon Ct, Katy, TX 77450
Professional information
Composition Comprising An Adenoviral Expression Vector Comprising A Cd40L Fusion Protein For Generating Immune Responses
US Patent:
8236295, Aug 7, 2012
Filed:
Feb 2, 2012
Appl. No.:
13/364370
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
A61K 48/00, C12N 15/00
US Classification:
424 932, 424 936, 4241991, 4353201
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.
Methods Of Generating Immune Responses With Compositions Comprising An Adenoviral Expression Vector Comprising A Cd40L Fusion Protein
US Patent:
8540979, Sep 24, 2013
Filed:
Jul 16, 2012
Appl. No.:
13/549581
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
A61K 48/00, C12N 15/00
US Classification:
424 932, 4241991, 4353201, 514 44 R
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.
Adenoviral Vector Vaccine
US Patent:
2014008, Mar 20, 2014
Filed:
Aug 23, 2013
Appl. No.:
13/974353
Inventors:
Albert B. Deisseroth - Potomac MD, US
Lixin Zhang - Houston TX, US
Lixin Zhang - Houston TX, US
Assignee:
VAXum, LLC - Manassas VA
International Classification:
C07K 14/705, C07K 14/005
US Classification:
4353201
Abstract:
Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which encodes the E6 or E7 protein of HPV. The immunity generated is long term.